

April 17, 2020

Listing Department
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400051

Code: CADILAHC

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated April 17, 2020 titled “Zydus receives final approval from the USFDA for Erlotinib Tablets”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above

Zydus receives final approval from USFDA for Erlotinib Tablets

Ahmedabad, April 17, 2020

Zydus Cadila has received final approval from the USFDA to market Erlotinib Tablets (US RLD: Tarceva® Tablets), in the strengths of 25 mg, 100 mg, and 150 mg.

Erlotinib is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. It is also used to treat non-small cell lung cancer or pancreatic cancer that has spread to other parts of the body (metastatic). Erlotinib is usually given after other cancer medicines have been tried without success.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, in Ahmedabad.

The group now has 288 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
